| 摘要 |
<p>The present invention relates to a lead compound UBP 502 with the formula ethyl -4- (5- (S-methylisoxazol-5-ylamino)pentyloxy)benzoate, and to a series of its analogs. UBP 502, compared to the reference compound R 77975 (Pirodavir) from the formula ethyl-4-(2-(l-(6-methylpirazine-3-iI)-43 pyperidil)etqxy benzoate presents, in vitro, a lesser cytpxicity combined with an adequate therapeutic index to envisage the potential clinical application. Moreover, when administered for oral route resulted to be bioavailable and metabolically stable compared to R 77975.</p> |
